Where the money is made: BioNTech, Novavax, Cardiol Therapeutics

BioNTech: Good starting position

Recently, the BioNTech share price experienced a minor shock: In the legal dispute with Moderna, the Mainz-based company filed a counterclaim with its partner Pfizer. The share price then dipped briefly - investors do not like legal disputes. However, the decline did not cloud the overall chart picture. BioNTech's share price is still driven by the Corona vaccine. Above all, the hope of orders from China makes investors' hearts beat faster. But BioNTech is also doing well in other regions of the world: most recently, Bahrain also opted for the adapted vaccine. Current studies show that the adapted vaccines are worthwhile. According to these, the antibody level in people over 55 years of age increases ninefold with the BQ1.1 variant.

Novavax: The air is out

Since BioNTech is flexibly positioned thanks to its mRNA technology and can also focus on other diseases, such as cancer, the stock remains promising. Although the stock is moving sideways between EUR 127 and EUR 176 in 2022, this could be a good starting point for rising prices towards old highs in the long term. The Novavax share also looks attractive from a chart perspective at first glance. However, a closer look reveals differences. First, Novavax does not rely on modern mRNA technology. In the race with the top dogs BioNTech and Moderna, Novavax cannot keep up with its delayed market entry. Only the vaccine against the RS virus, which is currently circulating strongly among children, gave hope for a while - but it ultimately failed in Phase 3 of the clinical trials. While the BioNTech share could regain its strength in the long term, Novavax is likely to have run out of steam for the time being.

Cardiol Therapeutics: Enormous comeback potential

At first glance, the air is also out of the Cardiol Therapeutics share. Within the past 14 months, the stock has plummeted from around USD 4.60 to the current level of USD 0.52. What happened? The innovative biotech company, which focuses on inflammatory diseases of the heart, raised fresh capital in 2021 to advance its clinical trials. Fortunately, it could do so at much higher prices than today. The general market environment and share dilution subsequently led to a sell-off at Cardiol. Finally, a few weeks ago, a research program to investigate the effect of the active ingredient CardiolRx in COVID patients was cancelled. Although the drug is still expected to be effective when COVID patients develop concomitant diseases such as myocarditis, the Company simply could not find enough patients to complete the study. Cardiol is now focusing on myocarditis, pericarditis and acute heart failure. Around the first two conditions, Cardiol Therapeutics is in Phase 2 of the development pipeline.

When pharmacologists are asked about the prospects for Cardiol Therapeutics, they praise the study design in particular. It is capable of producing clear results and also relies on modern methods. While the Novavax share has little chance of surprising positively with its current pipeline, the situation with Cardiol Therapeutics is different. The Company has the necessary capital and has launched promising studies. The active ingredient CBD is considered extremely low in side effects and has already demonstrated anti-inflammatory effects in many studies. Given the sell-off of the Cardiol Therapeutics share, investors should note the value - a dynamic catch-up movement cannot be ruled out here. It is worth keeping an eye on the newsflow! As soon as something happens here, the Nasdaq-listed stock should quickly be back in the focus of investors.